A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Terminated · Phase 2 · NCT05613088
Conditions: Neoplasms, Ovarian
At a glance
- Research payments reported, 2025
- $21,750
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 106
About the trial
- Sponsor
- Bristol-Myers Squibb (with Eisai Inc.)
- Tested
- MORAb-202 (drug), Paclitaxel (drug), Pegylated Liposomal Doxorubicin (PLD) (drug), Topotecan (drug)
- Dates
- Started 2023-02-01; completion 2025-09-10
- Results posted
- Yes
The purpose of the study is to assess the safety, tolerability, and efficacy of farletuzumab ecteribulin (MORAb-202) and compare it to Investigator's choice (IC) chemotherapy in female participants with platinum-resistant HGS ovarian, primary peritoneal, or fallopian tube cancer.
From ClinicalTrials.gov, last updated 2026-10-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $21,750 in research payments for this study in 2025 (1 payments).
Products named: Augtyro
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Gabrail Cancer Center Research $21,750
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.